Stay updated on P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.

Latest updates to the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page
- Check4 days agoChange DetectedThe page shows an updated revision label from v3.5.4 to v3.5.5, reflecting a version update rather than a change to the study details.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check26 days agoChange DetectedThe page revision label was updated from v3.5.3 to v3.5.4, indicating a new release version; no substantive changes to the displayed study information are evident.SummaryDifference0.1%

- Check47 days agoChange DetectedThe page’s release/version indicator was updated from “Revision: v3.5.2” to “Revision: v3.5.3,” reflecting a maintenance or platform update rather than a change to the study content.SummaryDifference0.1%

- Check55 days agoChange DetectedAdded Revision: v3.5.2; Removed Revision: v3.5.0.SummaryDifference0.1%

- Check83 days agoChange DetectedVersion update from v3.4.3 to v3.5.0; study details, eligibility criteria, and outcomes remain unchanged.SummaryDifference0.1%

- Check97 days agoChange DetectedRevision 3.4.3 was added and 3.4.2 was removed. No study details or interactive elements appear to be altered.SummaryDifference0.1%

Stay in the know with updates to P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.